FRAMINGHAM, MassachusettsGenzyme Molecular Oncology has launched a phase
I/II vaccine trial in advanced kidney cancer. The vaccine is made by
combining the patient’s own cancer cells with dendritic cells using an
electrical fusion approach. Up to 20 patients will be enrolled at Beth Israel
Deaconess Medical Center and the Dana-Farber Cancer Institute, Boston.
According to Genzyme, the cell fusion technology eliminates the need to
identify specific tumor proteins because the technique uses the entire tumor
cell to provide targets for the immune system to attack.